drugset / Trial / NCT01604057

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

NCT01604057

Phase 2 Unknown 130 enrolled Azelon Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.

Timeline

Start
2011-11
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject TERIPARATIDE Protein / enzyme biologic Intranasal
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications